ERBB2 and breast cancer: In the very first clinical trial with a radiolabeled nanobody, Keyaerts et al. demonstrated that 68Ga–NOTA–2Rs15d PET/CT enabled the visualization of both primary lesions and/or local or distant metastases in HER2-positive breast cancer patients, without adverse effects (Figure 1H).